J. Doroshow

发表

Microflora Trigger Colitis in Mice Deficient in Selenium-Dependent Glutathione Peroxidase and Induce Gpx2 Gene Expression

J. Doroshow, S. Binder, F. Chu, 2003, Biological chemistry.

Analysis of Candidate Colitis Genes in the Gdac1 Locus of Mice Deficient in Glutathione Peroxidase-1 and -2

Guillermo E. Rivas, J. Doroshow, F. Chu, 2012, PloS one.

Mice with combined disruption of Gpx1 and Gpx2 genes have colitis.

J. Doroshow, R. Esworthy, F. Chu, 2001, American journal of physiology. Gastrointestinal and liver physiology.

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

R. Fisher, C. Coltman, J. Doroshow, 1988, Annals of internal medicine.

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays.

Robin D Harrington, Chih-Jian Lih, Courtney H Bouk, 2016, The Journal of molecular diagnostics : JMD.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.

Y. Yen, Bingsen Zhou, B. Zhou, 1995, Cancer research.

Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

J. Doroshow, J. Wong, A. Wu, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

R. Fisher, M. Atkins, J. Sosman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

R. Fisher, M. Atkins, J. Sosman, 1997, The cancer journal from Scientific American.

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

R. Fisher, L. Rubinstein, M. Atkins, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of the microbiota in ileitis of a mouse model of inflammatory bowel disease—Glutathione peroxide isoenzymes 1 and 2‐double knockout mice on a C57BL background

J. Doroshow, F. Chu, B. Shen, 2020, MicrobiologyOpen.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

J. Doroshow, J. Wong, A. Wu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents.

J. Doroshow, J. H. Doroshow, J. Doroshow, 1986, Biochemical and biophysical research communications.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Jill P Mesirov, Lisa M McShane, James H Doroshow, 2013, BMC Medicine.

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

J. Doroshow, V. Israel, D. Gandara, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.

J. Doroshow, S. Akman, G. Forrest, 1990, Cancer research.

A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles.

J. Doroshow, R. Seshadri, T. Burke, 1989, Biochimica et biophysica acta.

Loss of 53 BP 1 causes PARP inhibitor resistance in BRCA 1-mutated mouse mammary tumors

Shridar Ganesan, James H. Doroshow, S. Ganesan, 2012 .

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lisa M McShane, Robin D Harrington, Chih-Jian Lih, 2017, The Journal of molecular diagnostics : JMD.

Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

D. Findley, J. Doroshow, R. Krance, 1987, Blood.

Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.

J. Doroshow, L. Leong, S. Akman, 1992, Cancer research.

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

R. Fisher, G. Weiss, J. Dutcher, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

J. Doroshow, W. Ye, L. Leong, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.

Y. Yen, L. Leong, P. Frankel, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.

Y. Yen, J. Doroshow, L. Leong, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.

J. Doroshow, L. Leong, S. Akman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells.

J. Doroshow, S. Akman, T. Burke, 1991, Free radical research communications.

Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.

J. Doroshow, T. Lee, T. Burke, 1991, Journal of pharmaceutical sciences.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.

P. Meltzer, J. Trent, J. Doroshow, 1990, Journal of the National Cancer Institute.

Methodologic guidelines for the design of high-dose chemotherapy regimens.

J. Doroshow, K. Margolin, J. Longmate, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

J. Doroshow, M. Slovak, F. Appelbaum, 2001, Blood.

Modulation of glutathione peroxidase expression by selenium: effect on human MCF-7 breast cancer cell transfectants expressing a cellular glutathione peroxidase cDNA and doxorubicin-resistant MCF-7 cells.

J. Doroshow, S. Akman, F. Chu, 1990, Nucleic acids research.

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

V. Sondak, J. Doroshow, C. Taylor, 1995, Journal of the National Cancer Institute.

Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI.

J. Doroshow, F. Chu, R. Esworthy, 1993, The Journal of biological chemistry.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

J. Doroshow, C. Takimoto, J. Grem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.

R. Fisher, J. Doroshow, G. Weiss, 1989, Journal of the National Cancer Institute.

Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.

J. Doroshow, E. Gajewski, S. Akman, 2001, Blood.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer.

J. Doroshow, W. Ye, L. Leong, 2011, Journal of Clinical Oncology.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

J. Doroshow, H. Lenz, A. El-Khoueiry, 2015, Cancer Chemotherapy and Pharmacology.

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

R. Bonow, J. Doroshow, S. Epstein, 1983 .

Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin.

J. Doroshow, K. Davies, Kelvin J.A. Davies, 1983, Biochemical pharmacology.